Background: In major depression, biological rhythm disturbances in sleep, appetite, and mood suggest dysregulation in neuroendocrine functions, possibly in the pineal gland. In this study, pineal gland function was examined by measuring nocturnal serum melatonin levels during both wakefulness and sleep in depressed children and adolescents.
Methods: Twenty-two youths aged 8 to 17 years primarily with major depression were compared with 19 controls. Blood samples were drawn every half hour from 6 PM to 7 AM. Nocturnal serum melatonin levels were measured by radioimmunoassay.
Results: The overall nocturnal serum melatonin profile from 6 PM to 7 AM was significantly higher (mean +/- SD, 0.18 +/- 0.14 nmol/L) in the depressed group than in the controls [mean +/- SD, 0.15 +/- 0.10 nmol/L, F(1,26) = 4.37, P < .05]. In dim light, when the subjects were awake, no difference existed between the 2 groups. After lights-out, from 10 PM to 7 AM, the melatonin profile rose in both groups; however, the depressed group had a significantly higher increase (mean +/- SD, 0.24 +/- 0.14 nmol/L) than the controls [mean +/- SD, 0.18 +/- 0.07 nmol/L, F(1,26) = 4.93, mean square error = 0.11, P = .04]. Post hoc analysis showed a significantly higher melatonin profile in depressed subjects without psychosis (n = 15) than in depressed subjects with psychosis (n = 7) or in the controls.
Conclusions: Measuring the overall nocturnal serum melatonin profile during darkness may help to differentiate children and adolescents with major depression without psychosis from those with psychosis and from controls.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archpsyc.1996.01830110047006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Pharmacokinetic/Pharmacodynamic Study of Esomeprazole Comparing a Dual Delayed-Release Formulation (YYD601) to a Conventional Formulation Following Multiple Administrations in Healthy Adult Subjects.
Drug Des Devel Ther
January 2025
School of Medicine, Kyungpook National University and Department of Clinical Pharmacology and Therapeutics, Kyungpook National University Hospital, Daegu, 41944, Republic of Korea.
Background: YYD601 is a new dual delayed-release formulation of esomeprazole, developed to enhance plasma exposure and prolong the duration of acid suppression.
Purpose: This study aimed to evaluate the safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of YYD601 20 mg following single and multiple oral administrations in healthy, fasting adult Koreans, and to compare these outcomes to those of the conventional esomeprazole 20 mg capsule.
Methods: A randomized, open-label, two-period crossover study was conducted in 28 participants, who were divided into two treatment groups: one group received YYD601 20 mg, and the other received conventional esomeprazole 20 mg, once daily for five consecutive days.
Case Report: A missed diagnosis of cardiac amyloidosis using echocardiography due to immunoglobulin light chain amyloidosis with normal wall thickness in the early stage.
Front Cardiovasc Med
December 2024
National Key Laboratory for Innovation and Transformation of Luobing Theory, Jinan, China.
Background: Cardiac amyloidosis (CA) is a challenging diagnosis, particularly when the classic signs, such as increased wall thickness in a non-dilated left ventricle (LV), are absent. This makes the diagnosis more difficult in patients with normal LV wall thickness. We present a case of CA without increased wall thickness and without the characteristic granular sparkling echotexture in a non-dilated LV.
View Article and Find Full Text PDFPatients with cirrhosis have high systemic inflammation (TNFα, CRP, and IL-6) that is associated with poor outcomes. These biomarkers need continuous non-invasive monitoring, which is difficult with blood. We studied the AWARE sweat-sensor to measure these in passively expressed sweat in healthy people (N = 12) and cirrhosis (N = 32, 10 outpatients/22 inpatients) for 3 days.
View Article and Find Full Text PDFNesfatin-1 is involved in hyperbaric oxygen-mediated therapeutic effects in high fat diet-induced hyperphagia in mice.
Peptides
January 2025
Department of Special Medicine, School of Basic Medicine, Qingdao University, Qingdao 266000, China. Electronic address:
Article Synopsis
- Obesity is a significant global health concern, and safe treatments are needed.
- The study explored hyperbaric oxygen (HBO) therapy as a potential method to reduce overeating and high energy intake in mice fed a high-fat diet.
- Results showed that HBO treatment decreased food intake and altered brain activity linked to hunger regulation, potentially involving the nesfatin-1 peptide and the melanocortin system.
KL‑6, ET‑1 and S100A9 levels in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea.
Exp Ther Med
January 2025
Department of Respiratory Medicine, University of Crete, School of Medicine, 71500 Crete, Greece.
Article Synopsis
- Obstructive sleep apnea (OSA) often occurs alongside idiopathic pulmonary fibrosis (IPF), and specific biomarkers like KL-6, ET-1, and S100A9 may help in diagnosing and understanding the severity of these conditions.
- A study involving 55 participants, including those with IPF and IPF-OSA, measured these biomarker levels and examined their relationship with various health factors.
- Although no significant differences in biomarker levels were found between groups, there were trends suggesting higher ET-1 in IPF-OSA, and significant correlations between KL-6 levels and IPF severity, indicating potential for these biomarkers in identifying OSA impact in IPF patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!